SCHEMBL25568265

SCHEMBL25568265

COC(=O)C1(CN=[N+]=[N-])CC(N(Cc2ccccc2)Cc2ccccc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.38
CCR5 P51681 1/20 0.37
TSHR P16473 4/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
NEU3 Q9UQ49 1/20 0.33
CYP3A4 P08684 3/20 0.33
ADAM17 P78536 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25568262 0.82 MAPT (0.40) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25568263 0.82 MAPT (0.40) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25568266 0.82 MAPT (0.40) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25568267 0.82 MAPT (0.42) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25568264 0.81 SLC6A2 (0.39) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25573149 0.78 CCR5 (0.37) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25573147 0.78 CCR5 (0.37) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL20690478 0.76 CCR5 (0.43) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25572909 0.74 MAPT (0.37) CCR5TSHRALDH1A1SMN1; SMN2ALOX15
SCHEMBL25699122 0.74 MAPT (0.37) CCR5TSHRALDH1A1SMN1; SMN2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091438-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM MYC 1656/4885CCR5 993/4885TSHR 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.